OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
December 10, 2024 07:00 ET
|
OnKure Therapeutics, Inc.
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels...
OnKure Announces New Date for Upcoming Investor Call
November 25, 2024 17:31 ET
|
OnKure Therapeutics, Inc.
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in...
OnKure to Present at the Stifel 2024 Healthcare Conference
November 05, 2024 16:05 ET
|
OnKure Therapeutics, Inc.
BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in...
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
November 01, 2024 17:30 ET
|
OnKure Therapeutics, Inc.
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE...
OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
July 25, 2024 18:43 ET
|
OnKure, Inc.
BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific Officer. In this position, Dr. Hartley...
OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary
June 19, 2024 17:42 ET
|
OnKure, Inc.
BOULDER, Colo., June 19, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Rogan Nunn as General Counsel and Secretary. Mr. Nunn will be a member of OnKure’s Executive Team,...
OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
February 15, 2024 09:31 ET
|
OnKure, Inc.
BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H. as Chief Medical Officer. Dr. Agresta brings more than 15 years of...
OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219
January 04, 2024 09:00 ET
|
OnKure, Inc.
BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of OKI-219,...
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
September 20, 2023 09:41 ET
|
OnKure, Inc.
BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces $54 Million Series C Financing
May 23, 2023 07:00 ET
|
OnKure, Inc.
BOULDER, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing. The financing was led...